EAC Harmonisation and Regional Reliance for Medical Devices in Kenya

Content verification date: October 30, 2026

1. Key takeaways

• Kenya’s regional harmonisation power has a statutory basis, but its nature is authorisation, not obligation. Section 3B(2)(r) of the Pharmacy and Poisons Act (Cap. 244) authorises PPB to cooperate with other countries and with regional and international institutions in the regulation of medicinal substances, and on that basis to recognise and rely on their registrations and certifications; Rule 7 of LN 100 of 2022 further provides that PPB may collaborate with other regulators or institutions on matters of common interest or specification investigations.
• Both provisions use may, not shall. This means approval in Kenya does not automatically produce effects in other member states of the East African Community (EAC).
• The reliance routes point to 8 Reference Regulatory Agencies (RRA): TGA, Health Canada, US FDA, EU Notified Bodies, MHLW, HPRA, SFDA and Swiss Medic. GRZAN notes that not one of them is an EAC member state agency.
• The practical value of a Kenyan approval for neighbouring markets is evidentiary spillover rather than effect spillover: as a high-maturity jurisdiction in the region, Kenya’s registration records can serve as supporting material in filings in other African jurisdictions, but each country requires a separate filing.
• The reverse direction is where the value lies: Kenya’s reliance routes are a structural advantage for companies already holding CE or FDA approvals, and IBR can list a product on the PPB online register within 1 hour.

2. Legal basis

3. Expert insights

Insight 1: the difference between may and shall caps the spillover

Section 3B(2)(r) and Rule 7 are both drafted as powers. GRZAN considers this drafting difference the key to understanding the regional effect of Kenyan approvals. If the provisions were obligatory, a Kenyan approval would carry a recognition duty in other member states; as powers, they leave PPB discretion over whether to cooperate, with whom, and on which matters. Going further, the express reservation that PPB remains independently responsible for its own decisions shows that even where Kenya relies on another regulator’s decision, it does not commit that decision to any effect in a third country. When planning East African market presence, companies should not write the Kenyan registration into their business plans as a regional passport.

Insight 2: the list of eight RRAs reveals where harmonisation really points

The list itself is the answer. All 8 RRAs are agencies of Australia, Canada, the United States, the EU, Japan, Ireland, Saudi Arabia and Switzerland, none from the EAC or the African continent. GRZAN therefore concludes that Kenya’s reliance routes are reliance on high-maturity jurisdictions, aimed at easing its own review burden by borrowing the conclusions of mature agencies; EAC-internal cooperation currently remains at the level of information exchange and joint investigations, without a mutual recognition channel. This matches Rule 7 limiting collaboration to matters of common interest or specification investigations: the object of cooperation is problems, such as falsification, substandard goods and cross-border violations, not conclusions, such as approvals and certificates.

Insight 3: Rule 7 cooperation points to enforcement, not market access

Rule 7 defines the scope of collaboration as matters of common interest or specification investigations. GRZAN notes that this aligns closely with Kenya’s current policy moves: the Inter-sectoral Steering Committee of the National Action Plan on Substandard and Falsified Medical Products launched on July 1, 2026, together with cross-border governance of falsified and substandard products, is the typical form of a matter of common interest. Companies operating across several East African countries should anticipate not the risk that one country penalises while others stay unaware, but chain reactions under regulatory information sharing: a model dealt with in Kenya may attract simultaneous attention in other member states.

Insight 4: the real spillover value of a Kenyan approval sits at the evidence level

GRZAN positions the value of a Kenyan approval in three classes. The first is evidentiary value: PPB registration certificates, retention records and clean adverse event records can support marketing history and safety claims in filings in other African jurisdictions. The second is systems value: Kenya’s strict demands on CSDT and ISO 13485 force companies to build a documentation system that can be reused directly in other jurisdictions. The third is anchor value: with Kenya as the regional hub, the LAR network, vigilance and traceability can be managed centrally and reused by neighbouring countries. All three classes of value must be organised deliberately by the company; none of them happens automatically.

4. Practical recommendations

1. Do not present Kenyan registration as a regional passport. GRZAN recommends listing registration requirements and timelines country by country in East African business plans, never substituting a Kenyan certificate for another country’s filing.
2. Turn Kenyan materials into a regional document master. Build a unified technical document library around the CSDT and extract per-country formats at filing time, avoiding repeated preparation.
3. Verify RRA reliance rules country by country. Before entering each East African jurisdiction, confirm its recognised reference agency list and reliance route thresholds.
4. Monitor cross-border enforcement information. Circulate Kenyan suspension, revocation and recall records internally and assess knock-on risks in other member states.
5. Use Kenya as the regional compliance hub. Manage the LAR network, vigilance reporting and batch traceability centrally, radiating to neighbouring countries.
6. Retain every compliance trace in Kenya. Archive retention receipts, vigilance reports and inspection records systematically, so they can serve as marketing history evidence in filings elsewhere.

5. Verification checklist

• □ Does the East African market plan list registration requirements country by country, without substituting the Kenyan certificate?
• □ Has a reusable technical document master been built around the CSDT for other jurisdictions?
• □ Have the RRA lists and reliance route thresholds of each target jurisdiction been verified country by country?
• □ Is an internal circulation mechanism in place for Kenyan suspension, revocation and recall records?
• □ Are the regional LAR network, vigilance reports and batch traceability managed centrally?
• □ Are retention receipts, vigilance reports and inspection records archived systematically and usable in filings elsewhere?
• □ Is it documented that section 3B(2)(r) and Rule 7 are enabling provisions that create no mutual recognition duty?

Regulatory information verified as of October 30, 2026.

In African markets, the GRZAN regulatory team focuses on Kenya, Nigeria, South Africa and Egypt and verifies every published regulatory conclusion against official gazettes, competent authority guidelines and public legal databases, with the verification date marked; figures, cycles and amounts not locatable in official sources are marked as practical estimates, not presumed.

GRZAN services cover market access strategy and risk classification; preparation and review of dossiers in CSDT, STED and CTD formats; selection and management of Local Authorized Representatives (LAR); QMS and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import clearance and PVoC coordination; regulatory intelligence subscriptions and compliance ledgers.

For East African regulatory planning, regional documentation strategy and multi-country compliance in Kenya and beyond, please contact the GRZAN regulatory team at info@grzanglobal.com.